Cargando…

Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study

OBJECTIVES: To assess the safety of an AS03-adjuvanted split virion H1N1 (2009) vaccine (Pandemrix) in persons vaccinated during the national pandemic influenza vaccination campaign in the UK. DESIGN: Prospective, cohort, observational, postauthorisation safety study. SETTING: 87 general practices f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nazareth, Irwin, Tavares, Fernanda, Rosillon, Dominique, Haguinet, François, Bauchau, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586178/ https://www.ncbi.nlm.nih.gov/pubmed/23388195 http://dx.doi.org/10.1136/bmjopen-2012-001912

Ejemplares similares

Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series
por: Cohet, Catherine, et al.
Publicado: (2016)

Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt
por: Dos Santos, Gaël, et al.
Publicado: (2017)

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
por: Pauksens, Karlis
Publicado: (2013)

A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice
por: Nachbagauer, Raffael, et al.
Publicado: (2016)

Safety and immunogenicity of AS03(B) adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
por: Waddington, Claire S, et al.
Publicado: (2010)

AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets
por: Stadlbauer, Daniel, et al.
Publicado: (2021)

Risk of Narcolepsy Associated with Inactivated Adjuvanted (AS03) A/H1N1 (2009) Pandemic Influenza Vaccine in Quebec
por: Montplaisir, Jacques, et al.
Publicado: (2014)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
por: Vaughn, David W, et al.
Publicado: (2014)

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03(A)-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
por: Heijmans, Stéphane, et al.
Publicado: (2011)

Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England
por: de Lusignan, Simon, et al.
Publicado: (2017)

Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England
por: Winstone, Anne Marie, et al.
Publicado: (2014)

Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of Two Methods; Germany, 2009/10
por: Uphoff, Helmut, et al.
Publicado: (2011)

Optimizing influenza vaccine policies for controlling 2009-like pandemics and regular outbreaks
por: Chen, Sheng-I, et al.
Publicado: (2019)

Origins of the 2009 H1N1 influenza pandemic in swine in Mexico
por: Mena, Ignacio, et al.
Publicado: (2016)

Multi-Centre Observational Study of Transplacental Transmission of Influenza Antibodies following Vaccination with AS03(A)-Adjuvanted H1N1 2009 Vaccine
por: Puleston, Richard, et al.
Publicado: (2013)

Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine
por: De Serres, Gaston, et al.
Publicado: (2012)

Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
por: Duval, Xavier, et al.
Publicado: (2012)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Time trends in the incidence of clinically diagnosed type 2 diabetes and pre-diabetes in the UK 2009–2018: a retrospective cohort study
por: Pal, Kingshuk, et al.
Publicado: (2021)

531 Split-virion compared to Subunit Influenza Trivalent Influenza Vaccines Has Greater Effectiveness in Older Adults
por: Talbot, H. Keipp, et al.
Publicado: (2014)

Estimates of hospitalization attributable to influenza and RSV in the US during 1997–2009, by age and risk status
por: Matias, Gonçalo, et al.
Publicado: (2017)

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria
por: Poeppl, W., et al.
Publicado: (2011)

Estimates of mortality attributable to influenza and RSV in the United States during 1997–2009 by influenza type or subtype, age, cause of death, and risk status
por: Matias, Gonçalo, et al.
Publicado: (2014)

Transmissibility of the 2009 H1N1 pandemic in remote and isolated Canadian communities: a modelling study
por: Mostaço-Guidolin, Luiz C, et al.
Publicado: (2012)

Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults
por: Lazarus, Rajeka, et al.
Publicado: (2016)

Enhanced Immunogenicity, Mortality Protection, and Reduced Viral Brain Invasion by Alum Adjuvant with an H5N1 Split-Virion Vaccine in the Ferret
por: Layton, Robert Colby, et al.
Publicado: (2011)

EPID-03. Epidemiology, treatment and outcomes of children and young adults with CNS tumors in Armenia
por: Hoveyan, Julieta, et al.
Publicado: (2022)

Evaluation of immune response following one dose of an AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older
por: Ikematsu, Hideyuki, et al.
Publicado: (2012)

Comparing the Immunogenicity of AS03-Adjuvanted 2009 Pandemic H1N1 Vaccine with Clinical Protection in Priority Risk Groups in England
por: Yung, Chee-Fu, et al.
Publicado: (2013)

A cell‐based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models
por: Cox, Rebecca J., et al.
Publicado: (2009)

Native Morphology of Influenza Virions
por: Noda, Takeshi
Publicado: (2012)

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
por: Drooger, Jan C., et al.
Publicado: (2016)

Adaptive Mutations in Influenza A/California/07/2009 Enhance Polymerase Activity and Infectious Virion Production
por: Slaine, Patrick D., et al.
Publicado: (2018)

Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis
por: Wijlaars, Linda P M M, et al.
Publicado: (2013)

Serum uric acid and the risk of respiratory disease: a population-based cohort study
por: Horsfall, Laura J, et al.
Publicado: (2014)

EPID-03. COMPARISON OF SURVIVAL IN ADULT AND PEDIATRIC PATIENTS WITH MEDULLOBLASTOMA: A 2018 SEER BASED ANALYSIS
por: Moisander-Joyce, Hanna M, et al.
Publicado: (2020)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Meta‐analysis of the risk of autoimmune thyroiditis, Guillain‐Barré syndrome, and inflammatory bowel disease following vaccination with AS04‐adjuvanted human papillomavirus 16/18 vaccine
por: Rosillon, Dominique, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3f55di6764kri0u1grmo3fgij4